Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Entero Therapeutics ( (ENTO) ).
On February 3, 2025, Entero Therapeutics announced a significant restructuring of its Board of Directors. The company appointed Manpreet Uppal, Alson Niu, and Richard Joel Paolone as new directors, replacing Timothy Ramdeen, Alastair Riddell, and James Sapirstein. However, on February 5, 2025, Alson Niu resigned and was replaced by Eric Corbett. These changes are expected to impact the company’s governance structure, with the new directors bringing diverse expertise in capital markets, corporate finance, and legal matters.
More about Entero Therapeutics
YTD Price Performance: -15.38%
Average Trading Volume: 202,419
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.61M
For detailed information about ENTO stock, go to TipRanks’ Stock Analysis page.